HAMILTON THORNE LTD. |
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.935 EUR | 0.00% |
|
+0.54% | -2.09% |
| Jun. 23 | Hamilton Thorne Maintained at Buy at Stifel GMP on No Impact From U.S. IVF Actions; Price Target Kept at C$2.55 | MT |
| May. 14 | Hamilton Thorne Q1 Loss Widens Even as Sales Increase | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental configuration.
Strengths
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
- Predictions on business development from analysts polled by Standard & Poor's are tight. This results from either a good visibility into core activities or accurate earnings releases.
Weaknesses
- The company does not generate enough profits, which is an alarming weak point.
- The company's valuation in terms of earnings multiples is rather high. Indeed, the firm is getting paid 85.78 times its estimated earnings per share for the ongoing year.
- For the last 12 months, analysts have been regularly downgrading their EPS expectations. Analysts predict worse results for the company against their predictions a year ago.
- For the last four months, earnings estimated by analysts have been revised downwards with respect to the next two years.
Ratings chart - Surperformance
Sector: Advanced Medical Equipment & Technology
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| -2.09% | 161M | - | ||
| +4.64% | 212B | B | ||
| +8.99% | 187B | B- | ||
| +29.83% | 155B | B- | ||
| +35.17% | 115B | A- | ||
| +1.90% | 65.5B | A- | ||
| +15.06% | 52.87B | B+ | ||
| -6.47% | 45.25B | B+ | ||
| -2.14% | 39.7B | A | ||
| +6.88% | 37.72B | - |
Investor Rating
Trading Rating
ESG Refinitiv
-
Financials
Sales growth
Earnings Growth
-
EBITDA / Sales
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
-
Price to Free Cash Flow
Yield
-
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- HTL Stock
- 0ZM Stock
- Ratings Hamilton Thorne Ltd.
